{
    "body": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19509115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12697967", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19783717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8613066", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21779504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8178941", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16757361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16166322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19826477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21626008", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21886451"
    ], 
    "ideal_answer": [
        "Activating point mutations most frequently in codon 12"
    ], 
    "exact_answer": [
        "Point mutations"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011905", 
        "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0032856", 
        "http://www.disease-ontology.org/api/metadata/DOID:305"
    ], 
    "type": "factoid", 
    "id": "5177def18ed59a060a000034", 
    "snippets": [
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 79, 
            "text": "activating mutations in KRAS are identified in most pancreatic cancers", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757361", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 182, 
            "text": "Mutations at codon 12 of the K-ras gene are present in 65%-100% of carcinomas of human exocrine pancreas and could be used as a potential tumor marker at the tissue level.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8613066", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 167, 
            "text": "Activating point mutations in the K-Ras oncogene are among the most common genetic alterations in pancreatic cancer, occurring early in the progression of the disease.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509115", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 140, 
            "text": "Activating K-ras mutations are found in approximately 90% of pancreatic carcinomas and may contribute to the poor prognosis of these tumors.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16166322", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1056, 
            "offsetInEndSection": 1216, 
            "text": "Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8178941", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1050, 
            "offsetInEndSection": 1095, 
            "text": "Ki-RAS mutations in 38% of the overall series", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12697967", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 533, 
            "offsetInEndSection": 665, 
            "text": "KRAS exon 2 mutations were detected in a total of 62 patients with the two methods combined, comprising 11 different mutant alleles.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19783717", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 119, 
            "text": "gain-of-function mutations in ras genes were the first specific genetic alterations identified in human cancer", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21779504", 
            "endSection": "sections.0"
        }
    ]
}